Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion by Tse, Longping Victor et al.
Structure-guided evolution of antigenically distinct
adeno-associated virus variants for immune evasion
Longping Victor Tsea, Kelli A. Klinca, Victoria J. Madigana,b, Ruth M. Castellanos Riveraa, Lindsey F. Wellsa,
L. Patrick Havlika,b, J. Kennon Smithc,d, Mavis Agbandje-McKennac,d, and Aravind Asokana,b,e,1
aGene Therapy Center, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599; bDepartment of Genetics, The University of North Carolina
at Chapel Hill, Chapel Hill, NC; 27599; cDepartment of Biochemistry and Molecular Biology, University of Florida, Gainesville, FL 32611; dCenter for
Structural Biology, The McKnight Brain Institute, University of Florida, Gainesville, FL 32611; and eDepartment of Biochemistry and Biophysics, The
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
Edited by Kenneth I. Berns, University of Florida College of Medicine, Gainesville, FL, and approved May 9, 2017 (received for review March 22, 2017)
Preexisting neutralizing antibodies (NAbs) against adeno-associated
viruses (AAVs) pose a major, unresolved challenge that restricts
patient enrollment in gene therapy clinical trials using recombinant
AAV vectors. Structural studies suggest that despite a high degree of
sequence variability, antibody recognition sites or antigenic hotspots
on AAVs and other related parvoviruses might be evolutionarily
conserved. To test this hypothesis, we developed a structure-guided
evolution approach that does not require selective pressure exerted
by NAbs. This strategy yielded highly divergent antigenic footprints
that do not exist in natural AAV isolates. Specifically, synthetic variants
obtained by evolving murine antigenic epitopes on an AAV serotype
1 capsid template can evade NAbs without compromising titer, trans-
duction efficiency, or tissue tropism. One lead AAV variant generated
by combining multiple evolved antigenic sites effectively evades poly-
clonal anti-AAV1 neutralizing sera from immunized mice and rhesus
macaques. Furthermore, this variant displays robust immune evasion
in nonhuman primate and human serum samples at dilution factors as
high as 1:5, currently mandated by several clinical trials. Our results
provide evidence that antibody recognition of AAV capsids is con-
served across species. This approach can be applied to any AAV strain
to evade NAbs in prospective patients for human gene therapy.
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Adeno-associated viruses (AAVs) are helper-dependent par-voviruses that have been established as safe and effective
recombinant vectors for therapeutic gene transfer in humans.
Since the approval of the first AAV1-based gene therapy in 2012,
encouraging results from clinical trials involving AAV vectors for
gene therapy for Leber congenital amaurosis (1), hemophilia (2),
and other diseases have been reported (3). Although they use dif-
ferent natural AAV isolates, these gene therapy trials share the
same exclusion criteria, requiring low or undetectable anti-AAV
neutralizing antibody (NAb) titers in prospective patients seeking
to enroll (e.g., ClinicalTrials.gov NCT01620801, NCT02618915,
NCT01687608). This eligibility criterion was established owing to
the high prevalence of preexisting anti-AAV NAbs in the human
population arising from natural exposure; for instance, the overall
prevalence of human subjects with cardiac failure positive for anti-
AAV1 NAbs at titers >1:2 is ∼60%. Furthermore, most patients
with high NAb titers against AAV serotype 2 also have measurable
titers to AAV1, suggesting cross-reactivity between serotypes (4).
Mechanistically, it is well-known that NAbs can substantially reduce
gene transfer efficiency of AAV vectors by opsonization, which then
accelerates clearance, alters biodistribution, blocks cell surface re-
ceptor binding, and/or adversely impacts the postattachment steps
essential for efficient transduction (5, 6). Thus, the presence of
preexisting anti-AAV NAbs remains a major unaddressed challenge
for gene therapy (7).
Cryoelectron microscopy and 3D image reconstruction
(cryoreconstruction) are powerful techniques for studying the
structures of virus-antibody complexes. Although traditional
methods, such as peptide scanning and site-directed mutagenesis,
provided early insight into antigenic regions on the AAV capsid,
cryoreconstruction has been particularly instrumental in mapping
antigenic residues with high precision (8). By analyzing mixtures of
antigen-binding fragments (Fabs) of purified monoclonal anti-
bodies (mAbs) complexed with AAV capsids, cryoreconstruction
has been used to resolve the antigenic footprints of various sero-
types, including AAV1/6, AAV2, AAV5, and AAV8 (8–12).
Those studies helped map the majority of antigenic epitopes to
variable regions (VRs) on the AAV capsid surface.
Despite the diversity in amino acid sequences within the dif-
ferent VRs, cryoreconstruction strongly supports the idea that
the number of antigenic clusters is limited and shared by dif-
ferent AAV strains. This attribute appears to be evolutionarily
conserved, in that similar observations have been reported for
the antigenic structure of other autonomous parvoviruses (13–
15). However, owing to the overlap with receptor-binding foot-
prints and other domains involved in capsid assembly, the impact
of rationally modifying these antigenic epitopes on viral titer,
infectivity, and tropism cannot be readily predicted. Thus, a
comprehensive approach that combines structural information
and directed evolution is essential to tackle this problem.
Although humoral immunity to AAV capsids has been studied in
different animal models and humans (5), the relationships among
the different NAb responses are not well understood. Thus, to date,
most strategies evaluated to circumvent humoral immunity to AAV
vectors have hinged largely on a priori assumption that antibody
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recognition of AAV capsids is conserved across species. Here we
tested this hypothesis using AAV1 as a template, which we chose
because of the availability of extensive structural information per-
taining to this capsid complexed with different mAbs and its cognate
glycan receptor, sialic acid (SA) (9, 10, 16). We then combined
structural information from cryo-EM images of AAV1 capsids
complexed with three different murine mAbs and directed evolu-
tion without selective pressure from NAbs to generate antibody-
evading AAV variants. The newly evolved strains harbor synthetic
antigenic footprints with highly diverse amino acid sequences that
are not present in natural AAV isolates. We demonstrate that
the resulting strains have the potential to evade NAbs in mouse,
nonhuman primate (NHP), and human sera, thereby supporting
the notion that AAV antigenicity is evolutionarily conserved among
species and can be artificially evolved without affecting other cap-
sid functions.
Results
Structural Analysis of AAV-Antibody Complexes Enables an Iterative
Approach to Evolve AAV Variants.We analyzed previously resolved,
cryoreconstructed structures of AAV1 capsids complexed with
four different Fabs of mouse anti-AAV1 mAbs (9, 10). Annotation
of the density for the Fabs onto the AAV1 capsid surface revealed
that this subset of antibodies masks nearly the entire capsid surface
(Fig. 1A). We then identified a subset of capsid surface residues
(through the construction of 2D roadmap images, which pinpoint
the Fab contacts on the AAV1 surface) that lie within these anti-
genic footprints and are implicated in direct contact with the
Fig. 1. Structure-guided evolution of antigenically distinct AAV variants. (A) A 3D model of cryoreconstructed AAV1 capsid complexed with multiple mAbs.
The model depicts AAV1 complexed with the Fab densities of four different mAbs viewed along the twofold axis: ADK1a (yellow), ADK1b (magenta), 4E4
(cyan), and 5H7 (orange). (B) Contact residues and CAMs for four anti-AAV1 antibodies on the capsid surface in a Roadmap image generated by RIVEM (29).
Color codes of each antibody are same as above; in addition, overlapping residues between antibodies are colored individually: green, ADK1a and 4E4; gray,
4E4 and 5H7. (C) Individual antigenic footprints on the AAV1 capsid selected for engineering and AAV library generation. Three different AAV libraries were
subjected to five rounds of evolution on vascular endothelial cells coinfected with adenovirus to yield single region AAV-CAM variants. (D) Iterative engi-
neering and evolution of new antigenic footprints generated from single-region AAV-CAM variants. This approach yields antigenically distinct AAV-CAM
variants with footprints that have not yet emerged in nature.
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different antibodies (Fig. 1B). Further analysis and comparison
with different AAV serotypes revealed a prominent clustering of
capsid antigenic footprints at the threefold symmetry axis on the
capsid surface. Specifically, amino acid residues within
three surface regions—region IV (456-AQNK-459), region V (492-
TKTDNNNS-499), and region VIII (588-STDPATGDVH-597)—
were selected for saturation mutagenesis and generation of different
AAV libraries. It is important to note that the different capsid
antigenic motifs (CAMs) listed above are subsets of VRs IV, V, and
VIII (8). Each AAV capsid library was then subjected to five rounds
of directed evolution in vascular endothelial cells, which are highly
permissive to the parental AAV1 strain (Fig. 1C). AAV variants
were identified, and combination AAV libraries were engineered
using the latter as templates. Iterative rounds of evolution and
capsid engineering yielded antibody-evading AAV strains charac-
terized in the present study (Fig. 1D).
Antigenic Footprints on the AAV Capsid Surface Are Remarkably Plastic
and Evolvable. As outlined above, the structural determined AAV
region IV, V, and VIII libraries were subjected to five rounds of
directed evolution. Libraries were then sequenced using the Illu-
mina MiSeq system, with each unselected (parental) library se-
quenced at ∼2 × 106 reads and selected (evolved) libraries
sequenced at ∼2 × 105 reads. Demultiplexed reads were probed for
mutagenized regions of interest with a custom Perl script, with a
high percentage of reads mapping to these regions for all libraries
(Fig. S1A). At both the nucleotide and amino acid levels, all un-
selected libraries demonstrated high diversity and minimal bias to-
ward any particular sequence, whereas the evolved libraries showed
dramatically increased representation of one or more lead variants
(Fig. 2 A–C and E–G and Fig. S1B). Furthermore, within the top-
10 selected variants for each library, many amino acid sequences
showed similarities at multiple residues (Fig. 2 E–G). For instance,
in the evolved region V library, 97.55% of sequences spanning the
mutagenized region of interest read TPGGNATR, whereas minor
variants largely mimicked this sequence (Fig. 2F). In the case of
region VIII, we observed significant enrichment (86.6%) for a
variant with amino acid residues TADHDTKGV (Fig. 2G). The
evolved region IV library demonstrated higher plasticity (QVRG,
69.57%; ERPR, 14.05%; SGGR, 3.62%), as evidenced by the range
Fig. 2. Library diversity, directed evolution, and enrichment of distinct antigenic footprints. (A–D) Parental and evolved libraries were subjected to high-throughput se-
quencing using the Illumina MiSeq platform. Following analysis with a custom Perl script, enriched amino acid sequences were plotted in R for both the parental and
evolved libraries of region IV (A), region V (B), region VIII (C), and combined regions V + VIII (D). Each bubble represents a distinct capsid amino acid sequence with the area
proportional to the number of reads for that variant in the respective library. (E–H) Amino acid sequence representation was calculated for the 10 variants with the highest
representation in each library after subjection to evolution. Percentages represent the number of reads for the variant in the evolved library normalized to the total number
of reads containing the antigenic region of interest. “Other” sequences represent all other evolved library amino acid sequences not contained in the top-10 hits.
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of amino acid residues tolerated within that antigenic region
(Fig. 2A).
We then generated a combination AAV library (regions V and
VIII; Fig. 2D), which carries the lead epitope from the evolved
region V library and a randomized region VIII. Interestingly, sub-
jecting this library to directed evolution yielded the wild-type (WT)
AAV1 sequence in region VIII (92.27%), i.e., STDPATGDVH
(Fig. 2H). Although a second variant with the sequence
DLDPKATEVE was also enriched (by 1.4%) (Fig. 2D), this
observation demonstrates the evolutionary and structural con-
straints imposed by the interaction between region V and regions
VIII to maintain capsid integrity. Nevertheless, these results
corroborate the notion that antigenic footprints on the AAV
capsid surface are mutable and can be evolved into distinct
footprints while maintaining infectivity.
Individually Evolved AAV CAM Variants Retain Biochemical and
Biophysical Properties of the Parental AAV1 Serotype. Multiple
evolved AAV variants were selected from each library (annotated
with the abbreviation CAM) for subsequent characterization. Spe-
cifically, the different variants were CAM101-107 (region IV),
CAM108 (region V), and CAM109-116 (region VIII). All CAM
variants packaging the ssCBA-Luc genome were produced and their
transduction efficiencies assessed in vascular endothelial cells (Fig.
S2J). A single CAM variant from each evolved library that displayed
the highest transduction efficiency was shortlisted for further
characterization. Specifically, CAM106 (456-SERR-459), CAM108
(492-TPGGNATR-499), and CAM109 (588-TADHDTKGVL-597)
showed similar to modestly improved transduction efficiency com-
pared with parental AAV1 on vascular endothelial cells. These
observations support the notion that antigenic footprints can be
reengineered and evolved while maintaining or improving on the
endogenous attributes of the corresponding parental AAV strain.
Further evaluation of the physical properties of these lead CAM
variants confirmed that yield (vector genome titers), capsid mor-
phology (EM), and packaging efficiency (proportion of full to
empty particles) were comparable to those of parental AAV1 vec-
tors (Fig. S2 A–D).
Individual CAM Variants Evade Neutralization by mAbs. We first
evaluated the ability of single-region CAM variants to avoid
neutralization by mouse mAbs ADK1a, 4E4, and 5H7 described
earlier (9, 10). The three mAbs that we selected for these studies
were generated from mice immunized with AAV1 (6, 17). All three
mAbs bind to threefold protrusions on the capsid surface (8, 9). An
earlier study showed that 4E4 and 5H7 reduce AAV1 transduction
by affecting both the binding and postattachment steps essential for
host cell transduction (6). As shown in Fig. 3 A–C, each CAM
variant shows a distinct NAb evasion profile. As expected, parental
AAV1 was neutralized by all mAbs tested at different dilutions. The
CAM106 and CAM108 variants were resistant to neutralization by
4E4, whereas CAM109 was completely neutralized, similar to
AAV1 (Fig. 3A). These observations are consistent with the ob-
servation that 4E4 maps over regions IV and V, whereas region
VIII is located farther away from the capsid surface. We next de-
termined that CAM108 and CAM109 both avoided neutraliza-
tion by 5H7 (which maps over regions V and VIII), whereas
CAM106 was significantly affected by 5H7, similar to AAV1 (Fig.
3B). With ADK1a, which partially recognizes residues within region
IV at the top of the threefold protrusions, CAM106 was signifi-
cantly resistant to neutralization, whereas both CAM108 and
CAM109 were effectively neutralized (Fig. 3C).
In Vivo Neutralization Profile of CAM Variants Against mAbs. To
further test whether the ability of CAM variants to avoid neu-
tralization can be reproduced in vivo, AAV1 and CAM variants
packaging ssCBA-Luc were mixed with the corresponding mAbs
and injected i.m. into mice. In the absence of mAbs, all CAM
variants and AAV1 showed similar luciferase transgene expres-
sion in mouse muscle (Fig. 3E). In the presence of antibodies,
the neutralization profiles of the CAM variants corroborated the
results from in vitro studies. In brief, CAM106 was resistant to
ADK1a and 4E4, whereas CAM108 efficiently transduced mouse
muscle in the presence of 4E4 or 5H7, and CAM109 evaded
5H7 with high efficiency. Importantly, AAV1 transduction of
mouse muscle was completely abolished when coadministered
with any of these antibodies (Fig. 3 F–H). Quantitative analysis
of luciferase transgene expression by CAM variants normalized
to AAV1 confirmed these observations (Fig. 3I).
Iterative Engineering of Complex Antigenic Footprints on Single-
Region CAM Variants. Based on the promising results from our
mAb neutralization studies, we hypothesized that combining differ-
ent, evolved antigenic footprints will alter the capsid surface suffi-
ciently to prevent recognition and neutralization by antibodies. To
test this hypothesis, we generated three variants through a combi-
nation of rational mutagenesis, library generation, and iterative
evolution. First, we observed that rational combination of antigenic
footprints from CAM106 (region IV) and CAM108 (region V)
yielded a functional and stable AAV variant, dubbed CAM117 (re-
gion IV +V) (Fig. 4A), but specific amino acid residues on CAM108
(region V) and CAM109 (region VIII) were not structurally com-
patible when combined on the same capsid. This observation is
consistent with findings reported in other AAV libraries (18), in
which simultaneous mutagenesis of these epitopes on the same
capsid reduced viral titers, presumably owing to assembly defects.
However, it is important to note that this apparent drawback can
be addressed effectively by our iterative approach. Specifically, to
facilitate structural compatibility, we generated an AAV capsid
library on region VIII using CAM108 (region V) as a template.
After three iterative cycles of directed evolution on vascular endo-
thelial cells as described earlier, several viable variants were gen-
erated (Fig. 4A). After initial characterization, CAM125 (region V,
492-TPGGNATR-499; region VIII, 588-DLDPKATEVE-597) was
selected for further analysis. We then iteratively engineered a third
variant (CAM130) by grafting the evolved antigenic footprint from
CAM106 onto CAM125. The CAM130 variant contains the fol-
lowing amino acid residues in three distinct antigenic footprints:
region IV, 456-SERR-459; region V, 492-TPGGNATR-499; and
region VIII, 588-DLDPKATEVE-597 (Fig. 4A). All three itera-
tively engineered variants—CAM117, CAM125, and CAM130—
show physical attributes comparable to those of parental AAV1 with
regard to vector titers and ratio of full to empty particles (Fig. S2D–I).
CAM117, CAM 125, and CAM130 Evade Neutralizing Antisera from
Preimmunized Mice. To test whether antigenically distinct CAM
variants can evade polyclonal NAbs found in serum, we sero-
converted mice by immunization with WT AAV1 capsids.
Overall, antisera obtained from individual mice efficiently neu-
tralized parental AAV1, whereas CAM117, CAM125, and
CAM130 displayed increased resistance to neutralization (Fig. 4
B–D). In brief, we tested antisera dilutions ranging over two
orders of magnitude (1:3,200–1:50) to generate sigmoidal neu-
tralization curves. The serum concentration required for 50%
neutralization of transduction (ND50) was 2- to 16-fold higher
for each CAM variant compared with parental AAV1 in each
individual subject (Figs. 4 B–D). Furthermore, we observed an
incremental ability to evade NAbs with each iterative engineering/
evolution step. Specifically, the most antigenically distinct variant,
CAM130, showed an 8- to 16-fold improvement in resistance to
neutralization (ND50 >1:200; Fig. 4 B–D). These results corroborate
the idea that antigenic footprints on AAV capsids are modular and
cumulative in their ability to mediate NAb evasion. A similar, but
less robust trend was observed with regard to the neutralizing
potential of serum obtained from naïve mice used as a control
(Fig. 4E).
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CAM130 Efficiently Evades Neutralization by NHP Antisera. To vali-
date whether our approach can be translated in larger animal
models, we tested the ability of AAV1 and the lead variant,
CAM130, to evade NAbs generated in NHPs (rhesus macaques).
In brief, we subjected AAV vectors to neutralization assays using
sera collected at three different time points: preimmunization (naïve)
and 4 wk and 9 wk postimmunization. All macaques seroconverted
after immunization with NAb titers at the highest levels in week 4,
with declines at week 9 in subjects 1 and 2 and increased potency at
week 9 in subject 3 (Fig. 5). Moreover, naïve sera from subjects 1 and
3 before immunization could neutralize AAV1 effectively (Fig. 5 A
and G). Because AAV1 was first identified as a contaminant in
simian adenovirus stocks isolated from NHP tissue, we expected the
natural host (i.e., rhesus macaques) to harbor antibodies against
AAV1 capsids (19). We tested antisera dilutions ranging over two
orders of magnitude (1:320–1:5) to generate neutralization curves as
described earlier. Antisera obtained at 4 wk after immunization
neutralized AAV1 effectively at ND50 >1:320. In contrast,
CAM130 displayed a significant shift consistent with im-
proved resistance to neutralization (by approximately eightfold;
ND50 >1:40) compared with AAV1 (Fig. 5 B, E, and H). A
similar trend toward enhanced resistance to NAbs was observed
for CAM130 when evaluating antisera obtained at 9 wk post-
immunization (Fig. 5 C, F, and I). These results strongly support
the idea that antigenicity of AAV capsids can be engineered to
broadly evade NAbs from different animal species on the basis of
structural cues obtained from mouse mAb footprints.
CAM130 Efficiently Evades NAbs in NHP and Human Sera. To test
whether CAM130 can evade NAbs and display a better profile
compared with AAV1 in the general NHP and human populations,
we tested serum samples obtained from cohorts of 10 subjects each.
We evaluated a fixed serum dilution of 1:5 to reflect the currently
mandated exclusion criterion used in ongoing clinical trials for
Fig. 3. Neutralization profile of AAV1 and single region CAM variants against mouse mAbs in vitro and in vivo. (A–C) Different AAV strains, AAV1 (black
bars), CAM106 (red bars), CAM108 (blue bars), and CAM109 (green bars) evaluated against mAbs 4E4, 5H7, and ADK1a in HEK293 cells in vitro (1,000 vg/cell)
at different dilutions of hybridoma media. Relative luciferase transgene expression mediated by different vectors mixed with mAbs was normalized to no-
antibody controls. Error bars represent SD (n = 4). (D) Roadmap images of the threefold axis of each CAM mutant showing the location of newly evolved
antigenic footprints: CAM106 (red), CAM108 (blue), and CAM109 (green). (E–H) Luciferase expression in mouse hindlimb muscles injected with a dose of 2 ×
1010 vg of AAV1, CAM106, CAM108, and CAM109 vectors packaging ssCBA-Luc and mixed with different mAbs. Representative live animal images at 4 wk
postinjection are shown in the following subgroups: no- antibody control (E), 4E4 (1:500) (F), 5H7 (1:50) (G), and ADK1a (1:5) (H). (I) Quantitation of luciferase
activity mediated by different CAM variants relative to parental AAV1. Luciferase activity is expressed as photons/s/cm2/sr as calculated with Living Image
3.2 software. Error bars represent SD (n = 3).
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Fig. 4. Neutralization profiles of AAV1 and CAM variants in preimmunized mouse antisera. (A) Roadmap images of each antigenically distinct CAM variant
showing newly evolved footprints at the threefold symmetry axis: CAM117 (regions IV + V, purple), CAM125 (regions V + VIII, cyan) and CAM130 (regions IV +
V + VIII, orange). (B–E) Anti-AAV1 mouse serum from three individual animals (B–D) and control mouse serum (E) were serially diluted in twofold increments
from 1:50 to 1:3,200 and then coincubated with AAV vectors in vitro (5,000 vg/cell). The dotted red line represents NAb-mediated inhibition of AAV
transduction by 50%. Solid lines represent relative transduction efficiencies of AAV1 (black), CAM117 (purple), CAM125 (cyan), and CAM130 (orange) at
different dilutions of antisera. Error bars represent SD (n = 3).
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hemophilia and other indications requiring systemic AAV ad-
ministration. As shown in Fig. 6A, serum from NHP subjects p-A
and p-B displayed high NAb titers that completely neutralized
AAV1 and CAM130. At the other end of the spectrum, serum
samples p-I and p-J neutralized neither AAV1 nor CAM130. Serum
samples for subjects p-C–p-H efficiently neutralized AAV1 and
reduced transduction efficiency to below 50% of that of untreated
controls. None of these serum samples neutralized the antigenically
distinct CAM130 variant. Thus, CAM130 showed exceptional NAb
evasion in this cohort by evading 8 out of 10 serum samples
(Fig. 6A).
We then used a similar approach to test serum from 10 human
subjects using exclusion criteria (from 1:5 dilution to any detect-
able NAbs) mandated by several clinical gene therapy trials (e.g.,
ClinicalTrials.gov NCT01620801, NCT02618915, NCT01687608).
We segregated human sera into two high-titer (h-A and h-B), six
intermediate-titer (h-C–h-H) and two modest-titer subgroups.
CAM130 was able to evade polyclonal NAbs in human sera in
8 of the 10 samples tested, whereas AAV1 did so in only 2 of the
10 samples (Fig. 6B). Taken together, our findings studies strongly
support the idea that the three murine epitopes engineered in this
study are conserved across species, and that the antigenically dis-
tinct CAM130 variant has the potential to evade antisera in a
species-independent manner. Thus, our approach provides a road-
map for clinical translation and has the potential to significantly
expand the patient cohort.
Antibody Evading AAV Variants Can Be Evolved Without Altering the
Transduction Profile in Vivo.We compared the in vivo tissue tropism,
transduction efficiency, and biodistribution of CAM130 and the
parental AAV1 strain in mice. A dose of 1 × 1011 vector genomes
(vg)/mouse of AAV vectors packaging scCBh-GFP was injected i.v.
into 6- to 8-wk-old female BALB/c mice via the tail vein. At 3 wk
postinjection, CAM130 had an apparently enhanced cardiac GFP
expression profile compared with AAV1 (Fig. S3 A and B). A
modest yet significant (approximately twofold) increase in GFP-
positive cardiac myofibers was found in CAM130-treated animals
compared with the AAV1 cohort (Fig. S3G). However, when we
administered 1 × 1011 vg of AAV vectors packaging ssCBA-Luc
genomes i.v., the increase in luciferase activity within the heart
Fig. 5. Neutralization profiles of AAV1 and CAM130 in NHP antisera. Serum samples collected from three individual rhesus macaques collected preimmu-
nization (naïve) and postimmunization (at 4 wk and 9 wk) were serially diluted in twofold increments from 1:5 to 1:320 and coincubated with AAV vectors
in vitro (10,000 vg/cell). (A) Primate serum 1 (naïve). (B) Anti-AAV primate serum 1 (4 wk). (C) Anti-AAV primate serum 1 (9 wk). (D) Primate serum 2 (naïve).
(E) Anti-AAV primate serum 2 (4 wk). (F) Anti-AAV primate serum 2 (9 wk). (G) Primate serum 3 (naïve). (H) Anti-AAV primate serum 3 (4 wk). (I) Anti-AAV
primate serum 3 (9 wk). The dotted red line represents NAb-mediated inhibition of AAV transduction by 50%. Solid lines represent relative transduction
efficiencies of AAV1 (black) and CAM130 (orange) at different dilutions of antisera. Error bars represent SD (n = 3).
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compared with that seen in AAV1-treated mice was marginal
and not statistically significant (Fig. S3H). Thus, we conclude that
the CAM130 variant is as effective, if not slightly more effective,
than the parental AAV1 strain. We found no major differences
in transduction efficiency in other organs, including liver, lung,
brain, kidney, and spleen (Fig. S4A). Importantly, we found no
differences in the systemic biodistribution of CAM130 and
AAV1 vectors in major tissues, such as heart and liver (Fig. S4B).
In general, higher vector genome copy numbers (∼10-fold) were
recovered from the liver compared with cardiac tissue for both
CAM130 and AAV1 vectors (Fig. S4B).
To further compare the tropism of CAM130 and AAV1, we
evaluated the transduction profiles of these two strains after CNS
administration. A dose of 3 × 109 vg of AAV1 or CAM130 packaging
scCBh-GFP genomes were injected by intra-CSF administration in
neonatal mice. Both AAV1 and CAM130 spread well within the
brain, with a general preference for transducing the ipsilateral side
more readily than the contralateral side (Fig. S3 C and D). As seen
with cardiac tissue, a similar number of GFP-positive neurons was
observed for CAM130 compared with AAV1 (Fig. S3I). In particu-
lar, CAM130 appeared to selectively transduce neurons particularly
within the motor cortex, cortex, and, most prominently, in the hip-
pocampus, similar to AAV1 (Figs. S3 E and F). Taken together,
these in vivo results confirm that antigenic footprints on AAV
capsids can be engineered to effectively evade NAbs without com-
promising vector yield, cellular/tissue tropism, or transduction and
biodistribution profiles. We expect that this approach can be readily
extended to other AAV serotypes as well.
Discussion
Our present study hinges on the finding that structural deter-
minants of AAV capsid recognition by different NAbs tend to
overlap and form antigenic footprints shared among different
AAV isolates. In particular, a majority of antigenic determinants
cluster around the threefold symmetry axes on the AAV capsid.
In some cases, antigenic regions also have been mapped to the
twofold to fivefold wall region on AAV capsids (8); however, it is
highly likely that these antigenic footprints and other potential
new sites, if identified, could be iteratively engineered onto our
variants in a mutually exclusive fashion. At present, no experi-
mental or computational approaches are available for engi-
neering future antigenic variants of AAV before they emerge in
nature. Earlier engineering strategies to address the problem of
NAbs relied on the limited antigenic variability among different
natural AAV isolates and yielded chimeric or ancestral AAV
capsids (20–22). Complementarily, our approach explores the
entire sequence space for each amino acid residue within anti-
genic footprints located on any AAV capsid surface. Thus, the
evolved AAV-CAM variants described herein are antigenically
distinct and contain synthetic antigenic footprints not existent
in nature.
Early in our efforts, we observed a cumulative effect on the
ability of CAM variants to evade NAbs as we grafted multiple
new antigenic epitopes on the same capsid. However, not all
combinations yielded viable capsids, suggesting potential struc-
tural incompatibilities when combining different engineered
epitopes. To address this concern, we iteratively engineered a
second-generation AAV capsid library derived from CAM variants
evolved in the earlier round. This iterative approach resulted in
CAM variants that can be produced at high yields, are highly po-
tent, and demonstrate NAb evasion potential. Significantly, the
antigenically distinct AAV variant CAM130 has the ability to avoid
neutralization by mouse, NHP, and human antisera. These obser-
vations strongly support the idea that antigenic recognition of AAV
capsids is significantly conserved across animal and human species.
Although more comprehensive studies evaluating the seropreva-
lence of AAV CAM variants in prospective patients will be essen-
tial, the multispecies data described in this study provide a promising
path forward for clinical translation.
Another important implication of our proof-of-concept study
with AAV1 is that structure-guided evolution can be readily adap-
ted to modify other AAV serotypes as well as engineered strains. A
comprehensive (if not exhaustive) structural dataset is now available
for mAbs complexed with different AAV serotypes (8, 9), which
strongly supports the idea that antigenic determinants on different
AAV serotypes are evolutionarily conserved. Given that the anti-
genic residues cluster predominantly into overlapping footprints on
the capsid surface, our approach is likely to yield antigenically dis-
tinct variants derived from any AAV capsid template.
A critical aspect of our approach is that antigenic epitopes on
the AAV capsid can be artificially evolved while maintaining
endogenous functions. This finding significantly expands our
knowledge of various amino acid residues that can be tolerated
within antigenic footprints without affecting viral titer, in-
fectivity, and tropism. Specifically, AAV1 requires sialylated
glycans for cell surface attachment, which in turn determines
transduction efficiency (23). The SA-binding site of AAV1 was
resolved recently, revealing specific contact residues located in a
pocket at the base of the threefold protrusions similar to the
galactose binding site on AAV9 (16). Specific residues located
within the SA binding pocket include S268, D270, N271, N447,
S472, V473, N500, T502, and W503. The present study was
designed to avoid manipulation of these residues owing to their
involvement with SA binding and partial overlap with the region
encoding the assembly-activating protein in the WT AAV ge-
nome (24). Although we cannot rule out the possibility that the
newly evolved antigenic epitopes on the AAV CAM variants
alter SA binding or, consequently, the infectious pathway(s) of
parental AAV1, it is important to note that our approach en-
sures that yield or transduction efficiency is not adversely im-
pacted. Further analysis of the 3D structure of AAV CAM
variants, their receptor use, and infectious pathway(s) are likely
Fig. 6. Neutralization profile of AAV1 and CAM130 against individual NHP
and human serum samples. AAV1 and CAM130 packaging ssCBA-Luc
(10,000 vg/cell) were tested against NHP (A) and human (B) sera at 1:5 di-
lution to reflect clinically relevant exclusion criteria. The dotted red line
represents NAb-mediated inhibition of AAV transduction by 50%. Bars
represent relative transduction efficiencies of AAV1 (black) and CAM130
(orange). Error bars represent SD (n = 3).
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to shed more light on structure-function correlates of AAV CAM
variants and guide future clinical applications.
This proof-of-principle study suggests that CAM variants have
the potential for use in patients with anti-AAV NAbs arising due
to natural exposure or previous treatment with recombinant
vectors based on natural AAV serotypes. However, the exact
clinical implications of the approximate log-order increase in
resistance to NAbs by CAM130 compared with AAV1 remain
unclear. In this regard, the next steps will involve characteriza-
tion of the immune profile of CAM130 in a large cohort of pa-
tient serum samples, along with dose-finding studies in large
animal models.
It is also important to acknowledge that the newly evolved
capsid variants likely will elicit a different subset of NAbs on
injection, limiting repeated administration. Although CAM var-
iants can be reengineered further, if warranted, our structure-
guided approach complements other methods to circumvent
preexisting humoral immunity in prospective patients that are
currently being explored in preclinical studies (5). One promising
approach involves the use of immunosuppressive agents that can
mitigate NAb generation after vector dosing (25). Although the
side effects of these agents are well documented, this approach
may help develop treatment regimens that require vector
redosing. Studies also have demonstrated that several rounds of
plasmapheresis can lower NAb titers from high to medium levels
(as low as 1:20) in patients (26, 27); however, this approach does
not appear to be as effective in further reducing medium-to-low
NAb titers that preclude patient enrollment (27). Nevertheless,
combined use of plasmapheresis and antibody-evading CAM
variants in prospective patients with high NAb titers may effec-
tively address this challenge. Overall, our structure-guided ap-
proach demonstrates the potential to make gene therapy, silencing,
and/or editing modalities with recombinant AAV vectors available
to an expanded patient cohort.
Materials and Methods
Cells, Viruses, and Antibodies. HEK293 and MB114 cells (a kind gift from Linda
Van Dyk, University of Colorado) were maintained in DMEM supplemented
with 10% FBS (Thermo Fisher Scientific), 100 U/mL penicillin, and 10 μg/mL
streptomycin (Thermo Fisher Scientific) in 5% CO2 at 37 °C. Murine adeno-
virus 1 (MAV-1) was purchased from American Type Culture Collection and
amplified by infecting MB114 cells at a multiplicity of infection (MOI) of 1. At
day 6 postinfection (∼50% cytopathic effect), media containing progeny
MAV-1 viruses were harvested and centrifuged at 3,000 × g for 5 min, and
the supernatant was stored at −80 °C for subsequent evolution studies.
Mouse anti-AAV1 mAbs ADK1a, 4E4, and 5H7 have been described pre-
viously (6, 9, 17). Naïve human serum samples were purchased from Valley
Biomedical. Naïve serum from rhesus macaques was a kind gift from Yoland
Smith and Adriana Galvan (Yerkes National Primate Center, Emory Univer-
sity). Antisera against AAV1 capsids, generated by immunizing rhesus ma-
caques i.m. with AAV1 capsids, was a kind gift from Jonah Sacha (Oregon
National Primate Center). All mouse, human, and NHP sera used in this study
were heat-inactivated at 55 °C for 15 min before use.
Recombinant AAV Production, Purification, and Quantification. Recombinant
AAV vectors were produced by transfecting four 150-mm dishes containing
HEK293 cells at 70–80% confluence with polyethylenimine using the triple-
plasmid protocol. Recombinant vectors packaging single-stranded genomes
encoding firefly luciferase driven by the chicken β-actin promoter (ssCBA-Luc) or
self-complementary green fluorescence protein driven by a hybrid chicken
β-actin promoter (scCBh-GFP) were generated using this method. Subsequent
steps involving the harvesting of recombinant AAV vectors and downstream
purification were carried out using updated methods (28). Recombinant AAV
vector titers were determined by quantitative PCR with primers amplifying
AAV2 inverted terminal repeat regions, 5′-AACATGCTACGCAGAGAGGGAGTGG-3′
and 5′-CATGAGACAAGGAACCCCTAGTGATGGAG-3′.
Structural Modeling and Analysis of AAV Antigenic Footprints. Antigenic
footprints of AAV serotypes 1/6, AAV2, AAV5, and AAV8 were determined
using previously resolved structures of AAV capsids complexed with different
mouse mAbs (8, 9). To restrict diversity and maximize the efficiency of AAV
library generation, only amino acid residues directly in contact with anti-
bodies were included for analysis. Contact surface residues on each serotype
were either aligned by Clustal Omega or structurally superimposed using
PyMOL (Schrödinger). Structural alignment revealed that antibody foot-
prints from multiple serotypes overlap in close proximity to the threefold
symmetry axis or around the fivefold pore and close to the twofold de-
pression, especially at the twofold or fivefold wall (8, 9). Of these CAMs, we
determined that the majority of the antibodies analyzed have direct contact
with the threefold symmetry or the twofold or fivefold wall, supporting the
notion that these regions are critical antigenic determinants on the AAV
capsid (8, 9). For the present study, antigenic footprints for three distinct
mAbs (4E4, 5H7, and ADK1a) were visualized on the AAV1 capsid (Protein
Data Bank ID code 3NG9), and roadmap images were generated using
RIVEM (29).
Generation of AAV Capsid Libraries. AAV libraries were engineered through
saturation mutagenesis of amino acid residues within different antigenic
footprints associated with distinct mAbs described above. In brief, for Gibson
assembly, 12 oligos with an average length of 70 nt were ordered from IDT.
Each oligo contained at least 15–20 nt overlapping homology to the
neighboring oligos. Three oligos contained degenerate nucleotides within
genomic regions coding for different antigenic footprints. Plasmid libraries
were then generated by in vitro assembly of multiple oligos using High-
Fidelity Gibson Assembly Mix (New England BioLabs) according to the
manufacturer’s instructions. The assembled fragments were either PCR-
amplified for 10 cycles using Phusion HF (New England BioLabs) or directly
cloned into pTR-AAV1** plasmid between the BspEI and SbfI restriction
sites. Plasmid pTR-AAV1** contains genes encoding AAV2 Rep and AAV1
Cap with stop codons at positions 490 and 491 (AAV1 VP1 numbering) in-
troduced by site-directed mutagenesis (Agilent). The entire construct is
flanked by AAV2 inverted terminal repeats to enable packaging and repli-
cation of pseudotyped AAV1 libraries on helper virus coinfection. Of note,
the AAV1** capsid gene was incorporated before library cloning, to reduce
WT AAV1 plasmid contamination during cloning. Ligation reactions were
then concentrated and purified by ethanol precipitation. Purified ligation
products were electroporated into DH10B ElectroMax cells (Invitrogen) and
directly plated on multiple 5,245-mm2 bioassay dishes (Corning) to avoid bias
from bacterial suspension cultures. Plasmid DNA from pTR-AAV1CAM li-
braries were purified from pooled colonies grown on LB agar plates using
the Invitrogen Maxiprep Kit.
Evolution of AAV CAM Strains. Equal amounts (15 μg) of each pTR-AAV1CAM
library and the Ad helper plasmid pXX680 were transfected onto
HEK293 cells at 70–80% confluency on each 150-mm dish using poly-
ethylenimine to generate CAM viral libraries. AAV CAM libraries were pu-
rified using standard procedures described earlier. MB114 cells were seeded
on a 150-mm tissue culture dish overnight to reach 60–70% confluence
before inoculation with AAV CAM libraries at an MOI ranging from 1,000 to
10,000. At 24 h posttransduction, MAV-1 was added as a helper virus to
promote AAV replication. At 6 d postinfection with MAV-1 (50% cytopathic
effect), the supernatant was harvested, and DNase I-resistant vector ge-
nomes were quantified on day 7. Media containing replicating AAV strains
and MAV-1 obtained from each round of infection were then used as in-
oculum for each subsequent cycle, for a total of five rounds of evolution.
Subsequent iterative rounds of evolution were carried out in a similar
fashion with AAV capsid libraries containing different permutations and
combinations of newly evolved antigenic footprints.
Identification of Newly Evolved AAV Strains. To analyze the sequence diversity
of the parental and evolved AAV CAM libraries, DNase I resistant vec-
tor genomes were isolated from media and amplified by Q5 polymerase
for 10–18 cycles (New England BioLabs) using primers 5′-CCCTA-
CACGACGCTCTTCCGATCTNNNNNcagaactcaaaatcagtccggaagt-3′ and
5′-GACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNgccaggtaatgctcccatagc-3′.
Illumina MiSeq sequencing adaptor for multiplexing was added in a second
round of PCR using Q5 Polymerase with P5 and P7 primers. After each round
of PCR, the products were purified using the PureLink PCR Micro Kit (Thermo
Fisher Scientific). The quality of the amplicons was verified using a Bioanalyzer
(Agilent), and concentrations were quantified using a Qubit spectrometer
(Thermo Fisher Scientific). Libraries were then prepared for sequencing
with the Illumina MiSeq 300 Reagent Kit v2, following the manufacturer’s
instructions, and sequenced on the MiSeq system.
Sequencing Data Analysis. Demultiplexed reads were subjected to a quality
control check using FastQC (v.0.11.5), with no sequences flagged for poor
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quality, and analyzed via a custom Perl script (Dataset S1). In brief, raw se-
quencing files were probed for mutagenized regions of interest, and the
frequencies of different nucleotide sequences in this region were counted
and ranked for each library. Nucleotide sequences were also translated, and
these amino acid sequences were similarly counted and ranked. Amino acid
sequence frequencies across libraries were then plotted in the R graphics
package v3.2.4.
Isolation of AAV CAM Variants for Characterization. To characterize selected
clones from each library, DNase I-resistant vector genomeswere isolated from
media and amplified by Phusion HF (New England BioLabs) using primers
flanking the BspEI and SbfI sites. The PCR products were gel-purified,
subcloned into TOPO cloning vectors (Thermo Fisher Scientific), and sent
out for standard Sanger sequencing (Eton Bioscience). Unique sequences
were subcloned into an AAV helper plasmid backbone using BspEI and SbfI
sites. Unique recombinant AAV CAM variants were produced following an
updated AAV vector production protocol (28).
In Vitro Antibody and Serum Neutralization Assays. Here 25 μL of antibody or
antiserum (as specified for individual experiments) was mixed with an equal
volume containing recombinant AAV vectors (1,000-10,000 vg/cell) in tissue
culture-treated, black, glass- bottom 96-well plates (Corning) and then in-
cubated at room temperature for 30 min. Assay parameters were carefully
controlled as outlined previously (30). A total of 5 × 104 HEK293 cells in 50 μL
of medium was then added to each well, and the plates were incubated in
5% CO2 at 37 °C for 48 h. Cells were then lysed with 25 μL of 1× passive lysis
buffer (Promega) for 30 min at room temperature. Luciferase activity was
measured on a Victor 3 multilabel plate reader (PerkinElmer) immediately
after the addition of 25 μL of luciferin (Promega). All readouts were nor-
malized to controls with no antibody/antiserum treatment. Recombinant
AAV vectors packaging ssCBA-Luc transgenes were prediluted in DMEM +
5% FBS + penicillin-streptomycin and used in this assay.
In Vivo Antibody Neutralization Assay. Each hind limb of 6- to 8-wk-old female
BALB/c mice (Jackson Laboratory) was injected i.m. with 2 × 1010 AAV
packaging CBA-Luc premixed with three different mAbs—4E4, 5H7, and
ADK1a—at 1:500, 1:50, and 1:5 dilution, respectively, in a final volume of
20 μL. At 4 wk postinjection, luciferase activity was measured using a
Xenogen IVIS Lumina system (PerkinElmer) at 5 min after i.p. injection of
175 μL of in vivo D-luciferin (120 mg/kg; Nanolight) per mouse. Luciferase
activity was measured as photons/s/cm2/sr and analyzed using Living Image
3.2 software (Caliper Life Sciences).
Statistical Analysis. Statistical analysis was carried out with GraphPad Prism
software using an unpaired, two-tailed Student t test. In the figures, *P < 0.5,
**P < 0.05, ***P < 0.005, ****P < 0.0005, n.s. means not significant, and error
bars represent 1 SD.
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